Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
OCGNthis companyOcugen, Inc.	$0.94	-5.87×	-33.31×	91.83×	-6.97×	-126.5%	45.9%	-1425.7%	-1537.4%	557.7%	-278.6%	-14.1%	-2.72×	-0.24×	-12.13×	1.06×	0.0%	2	-6.2	2	C
ALMSAlumis Inc.	$6.39	-4.21×	27.54×	345.07×	-33.2×	-85.0%	85.5%	-1776.3%	-1011.7%	-80.8%	-120.2%	-4.5%	0.12×	0.21×	0×	4.34×	0.0%	2	0.06	1	C-
CMPXCompass Therapeutics, Inc.	$0.80	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
FULCFulcrum Therapeutics, Inc.	$3.70	-9.58×	2.05×	0×	-7.15×	-17.6%	0.0%	0.0%	0.0%	-21.5%	-23.8%	-8.4%	0.02×	2.6×	0×	27.4×	0.0%	2	10.2	3	B
LCTXLineage Cell Therapeutics, Inc.	$1.05	-5.96×	8.63×	26.4×	-5.09×	-251.4%	94.2%	-149.6%	-436.5%	-142.6%	-19.7%	-5.1%	0.05×	0.56×	0×	5.2×	0.0%	3	-3.44	1	C-
LXRXLexicon Pharmaceuticals, Inc.	$1.87	-8.21×	3.88×	8.38×	-10.76×	-701.5%	99.4%	-98.2%	-101.1%	-46.8%	-28.7%	-16.3%	0.58×	-0.67×	-5.87×	4.88×	0.0%	2	-6.05	1	D+
Peer median	—	-8.21×	4.3×	8.38×	-10.76×	-85.0%	85.5%	-98.2%	-101.1%	-46.8%	-28.7%	-5.8%	0.05×	0.32×	0×	5.2×	0.0%	2	-0.29	1	—